JP2005519977A - 近赤外蛍光造影剤および蛍光造影法 - Google Patents
近赤外蛍光造影剤および蛍光造影法 Download PDFInfo
- Publication number
- JP2005519977A JP2005519977A JP2003579524A JP2003579524A JP2005519977A JP 2005519977 A JP2005519977 A JP 2005519977A JP 2003579524 A JP2003579524 A JP 2003579524A JP 2003579524 A JP2003579524 A JP 2003579524A JP 2005519977 A JP2005519977 A JP 2005519977A
- Authority
- JP
- Japan
- Prior art keywords
- group
- substituted
- contrast agent
- compound
- infrared fluorescent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002872 contrast media Substances 0.000 title claims abstract description 56
- 238000000034 method Methods 0.000 title claims description 34
- 150000001875 compounds Chemical class 0.000 claims abstract description 58
- 125000003118 aryl group Chemical group 0.000 claims abstract description 31
- 125000001434 methanylylidene group Chemical group [H]C#[*] 0.000 claims abstract description 25
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 24
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims abstract description 19
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 10
- 238000003384 imaging method Methods 0.000 claims abstract description 8
- 229910052751 metal Inorganic materials 0.000 claims abstract description 4
- 239000002184 metal Substances 0.000 claims abstract description 4
- 150000003242 quaternary ammonium salts Chemical class 0.000 claims abstract description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 26
- 125000004432 carbon atom Chemical group C* 0.000 claims description 25
- 125000001424 substituent group Chemical group 0.000 claims description 20
- 230000005284 excitation Effects 0.000 claims description 18
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 claims description 12
- 125000001072 heteroaryl group Chemical group 0.000 claims description 11
- 125000005843 halogen group Chemical group 0.000 claims description 8
- 125000004181 carboxyalkyl group Chemical group 0.000 claims description 7
- 238000000799 fluorescence microscopy Methods 0.000 claims description 7
- 125000004964 sulfoalkyl group Chemical group 0.000 claims description 7
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 5
- 125000005647 linker group Chemical group 0.000 claims description 5
- 238000002583 angiography Methods 0.000 claims description 4
- 230000001678 irradiating effect Effects 0.000 claims description 4
- 229910052799 carbon Inorganic materials 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 2
- 150000003839 salts Chemical class 0.000 abstract description 8
- 230000035699 permeability Effects 0.000 abstract description 6
- 210000004204 blood vessel Anatomy 0.000 abstract description 5
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 abstract 1
- 125000006732 (C1-C15) alkyl group Chemical group 0.000 abstract 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 230000003472 neutralizing effect Effects 0.000 abstract 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 99
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 54
- 230000015572 biosynthetic process Effects 0.000 description 44
- 238000003786 synthesis reaction Methods 0.000 description 44
- -1 porphyrin compounds Chemical class 0.000 description 35
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical class CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 28
- 239000000243 solution Substances 0.000 description 28
- 239000000203 mixture Substances 0.000 description 27
- 239000013078 crystal Substances 0.000 description 26
- 238000005160 1H NMR spectroscopy Methods 0.000 description 18
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 18
- 238000001914 filtration Methods 0.000 description 16
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 15
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 15
- 239000002904 solvent Substances 0.000 description 14
- 238000006243 chemical reaction Methods 0.000 description 11
- 239000000975 dye Substances 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 239000011541 reaction mixture Substances 0.000 description 9
- ANRHNWWPFJCPAZ-UHFFFAOYSA-M thionine Chemical class [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 8
- 229940125782 compound 2 Drugs 0.000 description 8
- 230000003287 optical effect Effects 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 229940125904 compound 1 Drugs 0.000 description 7
- 125000000623 heterocyclic group Chemical group 0.000 description 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 7
- 229940126639 Compound 33 Drugs 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- PNUZDKCDAWUEGK-CYZMBNFOSA-N Sitafloxacin Chemical compound C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1 PNUZDKCDAWUEGK-CYZMBNFOSA-N 0.000 description 6
- 125000003545 alkoxy group Chemical group 0.000 description 6
- 125000003277 amino group Chemical group 0.000 description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 6
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 5
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 5
- KCBAMQOKOLXLOX-BSZYMOERSA-N CC1=C(SC=N1)C2=CC=C(C=C2)[C@H](C)NC(=O)[C@@H]3C[C@H](CN3C(=O)[C@H](C(C)(C)C)NC(=O)CCCCCCCCCCNCCCONC(=O)C4=C(C(=C(C=C4)F)F)NC5=C(C=C(C=C5)I)F)O Chemical compound CC1=C(SC=N1)C2=CC=C(C=C2)[C@H](C)NC(=O)[C@@H]3C[C@H](CN3C(=O)[C@H](C(C)(C)C)NC(=O)CCCCCCCCCCNCCCONC(=O)C4=C(C(=C(C=C4)F)F)NC5=C(C=C(C=C5)I)F)O KCBAMQOKOLXLOX-BSZYMOERSA-N 0.000 description 5
- 238000004440 column chromatography Methods 0.000 description 5
- 229940125833 compound 23 Drugs 0.000 description 5
- 229940125846 compound 25 Drugs 0.000 description 5
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- ABJSOROVZZKJGI-OCYUSGCXSA-N (1r,2r,4r)-2-(4-bromophenyl)-n-[(4-chlorophenyl)-(2-fluoropyridin-4-yl)methyl]-4-morpholin-4-ylcyclohexane-1-carboxamide Chemical compound C1=NC(F)=CC(C(NC(=O)[C@H]2[C@@H](C[C@@H](CC2)N2CCOCC2)C=2C=CC(Br)=CC=2)C=2C=CC(Cl)=CC=2)=C1 ABJSOROVZZKJGI-OCYUSGCXSA-N 0.000 description 4
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 4
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 4
- BQXUPNKLZNSUMC-YUQWMIPFSA-N CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 Chemical compound CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 BQXUPNKLZNSUMC-YUQWMIPFSA-N 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- 229940125773 compound 10 Drugs 0.000 description 4
- 229940126543 compound 14 Drugs 0.000 description 4
- 229940126214 compound 3 Drugs 0.000 description 4
- 229940125898 compound 5 Drugs 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 238000002073 fluorescence micrograph Methods 0.000 description 4
- 125000000524 functional group Chemical group 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 150000002430 hydrocarbons Chemical group 0.000 description 4
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- VUCMMJBDNXZQDJ-UHFFFAOYSA-N n-(5-phenyliminopenta-1,3-dienyl)aniline;hydrochloride Chemical compound Cl.C=1C=CC=CC=1NC=CC=CC=NC1=CC=CC=C1 VUCMMJBDNXZQDJ-UHFFFAOYSA-N 0.000 description 4
- 210000003462 vein Anatomy 0.000 description 4
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 125000003710 aryl alkyl group Chemical group 0.000 description 3
- 125000004429 atom Chemical group 0.000 description 3
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical group C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 229940125758 compound 15 Drugs 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 238000004163 cytometry Methods 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 3
- 238000002428 photodynamic therapy Methods 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- HCLGAQLMEOAUGE-UHFFFAOYSA-M potassium;methanol;acetate Chemical class [K+].OC.CC([O-])=O HCLGAQLMEOAUGE-UHFFFAOYSA-M 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000010898 silica gel chromatography Methods 0.000 description 3
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 125000000547 substituted alkyl group Chemical group 0.000 description 3
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 2
- RFFLAFLAYFXFSW-UHFFFAOYSA-N 1,2-dichlorobenzene Chemical compound ClC1=CC=CC=C1Cl RFFLAFLAYFXFSW-UHFFFAOYSA-N 0.000 description 2
- AIGNCQCMONAWOL-UHFFFAOYSA-N 1,3-benzoselenazole Chemical group C1=CC=C2[se]C=NC2=C1 AIGNCQCMONAWOL-UHFFFAOYSA-N 0.000 description 2
- BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 description 2
- ODIRBFFBCSTPTO-UHFFFAOYSA-N 1,3-selenazole Chemical group C1=C[se]C=N1 ODIRBFFBCSTPTO-UHFFFAOYSA-N 0.000 description 2
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
- HUFDYAIAEFHOKI-UHFFFAOYSA-N 2,3,3-trimethylindol-1-ium-5-sulfonate Chemical compound C1=C(S(O)(=O)=O)C=C2C(C)(C)C(C)=NC2=C1 HUFDYAIAEFHOKI-UHFFFAOYSA-N 0.000 description 2
- FLHJIAFUWHPJRT-UHFFFAOYSA-N 2,3,3-trimethylindole Chemical compound C1=CC=C2C(C)(C)C(C)=NC2=C1 FLHJIAFUWHPJRT-UHFFFAOYSA-N 0.000 description 2
- MONMFXREYOKQTI-UHFFFAOYSA-N 2-bromopropanoic acid Chemical compound CC(Br)C(O)=O MONMFXREYOKQTI-UHFFFAOYSA-N 0.000 description 2
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 2
- SYBYTAAJFKOIEJ-UHFFFAOYSA-N 3-Methylbutan-2-one Chemical compound CC(C)C(C)=O SYBYTAAJFKOIEJ-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- QMHIMXFNBOYPND-UHFFFAOYSA-N 4-methylthiazole Chemical compound CC1=CSC=N1 QMHIMXFNBOYPND-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- 229940126062 Compound A Drugs 0.000 description 2
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 2
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 2
- CFADUJNDPKHQBD-UHFFFAOYSA-N O.C=1C=CC=CC=1N=CC=CC(C)=CNC1=CC=CC=C1 Chemical compound O.C=1C=CC=CC=1N=CC=CC(C)=CNC1=CC=CC=C1 CFADUJNDPKHQBD-UHFFFAOYSA-N 0.000 description 2
- TYOXMPVNNVCHDZ-QRPNPIFTSA-N O.CC(C)(C)OC(=O)C[C@H](N)C(=O)OC(C)(C)C Chemical compound O.CC(C)(C)OC(=O)C[C@H](N)C(=O)OC(C)(C)C TYOXMPVNNVCHDZ-QRPNPIFTSA-N 0.000 description 2
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- 229920005654 Sephadex Polymers 0.000 description 2
- 239000012507 Sephadex™ Substances 0.000 description 2
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical group C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 2
- SMNRFWMNPDABKZ-WVALLCKVSA-N [[(2R,3S,4R,5S)-5-(2,6-dioxo-3H-pyridin-3-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4S,5R,6R)-4-fluoro-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)C2C=CC(=O)NC2=O)[C@H](O)[C@@H](F)[C@@H]1O SMNRFWMNPDABKZ-WVALLCKVSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 2
- 125000004414 alkyl thio group Chemical group 0.000 description 2
- 125000004103 aminoalkyl group Chemical group 0.000 description 2
- 150000003863 ammonium salts Chemical class 0.000 description 2
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- 125000005110 aryl thio group Chemical group 0.000 description 2
- KXNQKOAQSGJCQU-UHFFFAOYSA-N benzo[e][1,3]benzothiazole Chemical group C1=CC=C2C(N=CS3)=C3C=CC2=C1 KXNQKOAQSGJCQU-UHFFFAOYSA-N 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- 125000004966 cyanoalkyl group Chemical group 0.000 description 2
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 2
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 2
- 238000002059 diagnostic imaging Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 2
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 description 2
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 2
- 125000004464 hydroxyphenyl group Chemical group 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 238000002595 magnetic resonance imaging Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- XELZGAJCZANUQH-UHFFFAOYSA-N methyl 1-acetylthieno[3,2-c]pyrazole-5-carboxylate Chemical compound CC(=O)N1N=CC2=C1C=C(C(=O)OC)S2 XELZGAJCZANUQH-UHFFFAOYSA-N 0.000 description 2
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 2
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 238000011580 nude mouse model Methods 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 238000006722 reduction reaction Methods 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 125000003107 substituted aryl group Chemical group 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 125000004434 sulfur atom Chemical group 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- TXUICONDJPYNPY-UHFFFAOYSA-N (1,10,13-trimethyl-3-oxo-4,5,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl) heptanoate Chemical compound C1CC2CC(=O)C=C(C)C2(C)C2C1C1CCC(OC(=O)CCCCCC)C1(C)CC2 TXUICONDJPYNPY-UHFFFAOYSA-N 0.000 description 1
- RGGOWBBBHWTTRE-UHFFFAOYSA-N (4-bromophenyl)hydrazine;hydron;chloride Chemical compound Cl.NNC1=CC=C(Br)C=C1 RGGOWBBBHWTTRE-UHFFFAOYSA-N 0.000 description 1
- KSOXXQBOWNEUDA-UHFFFAOYSA-N (4-methyl-2-sulfanylphenyl)boronic acid Chemical compound CC1=CC=C(B(O)O)C(S)=C1 KSOXXQBOWNEUDA-UHFFFAOYSA-N 0.000 description 1
- UVNPEUJXKZFWSJ-LMTQTHQJSA-N (R)-N-[(4S)-8-[6-amino-5-[(3,3-difluoro-2-oxo-1H-pyrrolo[2,3-b]pyridin-4-yl)sulfanyl]pyrazin-2-yl]-2-oxa-8-azaspiro[4.5]decan-4-yl]-2-methylpropane-2-sulfinamide Chemical compound CC(C)(C)[S@@](=O)N[C@@H]1COCC11CCN(CC1)c1cnc(Sc2ccnc3NC(=O)C(F)(F)c23)c(N)n1 UVNPEUJXKZFWSJ-LMTQTHQJSA-N 0.000 description 1
- QEGNUYASOUJEHD-UHFFFAOYSA-N 1,1-dimethylcyclohexane Chemical group CC1(C)CCCCC1 QEGNUYASOUJEHD-UHFFFAOYSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- GTDUGNCNZNUGLP-UHFFFAOYSA-N 1,3-diethyl-2h-imidazo[4,5-b]quinoxaline Chemical compound C1=CC=C2N=C3N(CC)CN(CC)C3=NC2=C1 GTDUGNCNZNUGLP-UHFFFAOYSA-N 0.000 description 1
- VXNZUUAINFGPBY-UHFFFAOYSA-N 1-Butene Chemical group CCC=C VXNZUUAINFGPBY-UHFFFAOYSA-N 0.000 description 1
- FCTIZUUFUMDWEH-UHFFFAOYSA-N 1h-imidazo[4,5-b]quinoxaline Chemical group C1=CC=C2N=C(NC=N3)C3=NC2=C1 FCTIZUUFUMDWEH-UHFFFAOYSA-N 0.000 description 1
- 125000000143 2-carboxyethyl group Chemical group [H]OC(=O)C([H])([H])C([H])([H])* 0.000 description 1
- VHCSBTPOPKFYIU-UHFFFAOYSA-N 2-chloroethanesulfonyl chloride Chemical compound ClCCS(Cl)(=O)=O VHCSBTPOPKFYIU-UHFFFAOYSA-N 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- MHIITNFQDPFSES-UHFFFAOYSA-N 25,26,27,28-tetrazahexacyclo[16.6.1.13,6.18,11.113,16.019,24]octacosa-1(25),2,4,6,8(27),9,11,13,15,17,19,21,23-tridecaene Chemical compound N1C(C=C2C3=CC=CC=C3C(C=C3NC(=C4)C=C3)=N2)=CC=C1C=C1C=CC4=N1 MHIITNFQDPFSES-UHFFFAOYSA-N 0.000 description 1
- MUNOBADFTHUUFG-UHFFFAOYSA-N 3-phenylaniline Chemical group NC1=CC=CC(C=2C=CC=CC=2)=C1 MUNOBADFTHUUFG-UHFFFAOYSA-N 0.000 description 1
- 125000006201 3-phenylpropyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- WDBQJSCPCGTAFG-QHCPKHFHSA-N 4,4-difluoro-N-[(1S)-3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-pyridin-3-ylpropyl]cyclohexane-1-carboxamide Chemical compound FC1(CCC(CC1)C(=O)N[C@@H](CCN1CCC(CC1)N1C(=NN=C1C)C(C)C)C=1C=NC=CC=1)F WDBQJSCPCGTAFG-QHCPKHFHSA-N 0.000 description 1
- DRORSPJLYCDESA-UHFFFAOYSA-N 4,4-dimethylcyclohexene Chemical group CC1(C)CCC=CC1 DRORSPJLYCDESA-UHFFFAOYSA-N 0.000 description 1
- SJIKYDRMMAIJCS-UHFFFAOYSA-N 4-chloro-1,3-benzoselenazole Chemical compound ClC1=CC=CC2=C1N=C[se]2 SJIKYDRMMAIJCS-UHFFFAOYSA-N 0.000 description 1
- IFEPGHPDQJOYGG-UHFFFAOYSA-N 4-chloro-1,3-benzothiazole Chemical compound ClC1=CC=CC2=C1N=CS2 IFEPGHPDQJOYGG-UHFFFAOYSA-N 0.000 description 1
- QNDGTSQNWUXVEA-UHFFFAOYSA-N 4-chloro-1,3-benzoxazole Chemical compound ClC1=CC=CC2=C1N=CO2 QNDGTSQNWUXVEA-UHFFFAOYSA-N 0.000 description 1
- SRGCYOMCADXFJA-UHFFFAOYSA-N 4-methyl-4,5-dihydro-1,3-thiazole Chemical compound CC1CSC=N1 SRGCYOMCADXFJA-UHFFFAOYSA-N 0.000 description 1
- GHAFJOZKMUPGRQ-UHFFFAOYSA-N 4-nitro-1,3-oxazole Chemical compound [O-][N+](=O)C1=COC=N1 GHAFJOZKMUPGRQ-UHFFFAOYSA-N 0.000 description 1
- MLBGDGWUZBTFHT-UHFFFAOYSA-N 4-phenyl-1,3-selenazole Chemical compound [se]1C=NC(C=2C=CC=CC=2)=C1 MLBGDGWUZBTFHT-UHFFFAOYSA-N 0.000 description 1
- 238000011729 BALB/c nude mouse Methods 0.000 description 1
- UJKPHYRXOLRVJJ-MLSVHJFASA-N CC(O)C1=C(C)/C2=C/C3=N/C(=C\C4=C(CCC(O)=O)C(C)=C(N4)/C=C4\N=C(\C=C\1/N\2)C(C)=C4C(C)O)/C(CCC(O)=O)=C3C Chemical compound CC(O)C1=C(C)/C2=C/C3=N/C(=C\C4=C(CCC(O)=O)C(C)=C(N4)/C=C4\N=C(\C=C\1/N\2)C(C)=C4C(C)O)/C(CCC(O)=O)=C3C UJKPHYRXOLRVJJ-MLSVHJFASA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- LIQQDSFFUGIJFR-UHFFFAOYSA-N Cl.C=1C=CC=CC=1N=CC=C(C)C=CNC1=CC=CC=C1 Chemical compound Cl.C=1C=CC=CC=1N=CC=C(C)C=CNC1=CC=CC=C1 LIQQDSFFUGIJFR-UHFFFAOYSA-N 0.000 description 1
- DUHVQBLYNNZATN-UHFFFAOYSA-N Cl.C=1C=CC=CC=1N=CC=CC(C)=CNC1=CC=CC=C1 Chemical compound Cl.C=1C=CC=CC=1N=CC=CC(C)=CNC1=CC=CC=C1 DUHVQBLYNNZATN-UHFFFAOYSA-N 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical class NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- 206010034972 Photosensitivity reaction Diseases 0.000 description 1
- 102100028255 Renin Human genes 0.000 description 1
- 108090000783 Renin Proteins 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229910021626 Tin(II) chloride Inorganic materials 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 235000010724 Wisteria floribunda Nutrition 0.000 description 1
- ABRVLXLNVJHDRQ-UHFFFAOYSA-N [2-pyridin-3-yl-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound FC(C1=CC(=CC(=N1)C=1C=NC=CC=1)CN)(F)F ABRVLXLNVJHDRQ-UHFFFAOYSA-N 0.000 description 1
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 1
- 238000007259 addition reaction Methods 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 125000005530 alkylenedioxy group Chemical group 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 150000001483 arginine derivatives Chemical class 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- AMTXUWGBSGZXCJ-UHFFFAOYSA-N benzo[e][1,3]benzoselenazole Chemical compound C1=CC=C2C(N=C[se]3)=C3C=CC2=C1 AMTXUWGBSGZXCJ-UHFFFAOYSA-N 0.000 description 1
- WMUIZUWOEIQJEH-UHFFFAOYSA-N benzo[e][1,3]benzoxazole Chemical compound C1=CC=C2C(N=CO3)=C3C=CC2=C1 WMUIZUWOEIQJEH-UHFFFAOYSA-N 0.000 description 1
- IEICFDLIJMHYQB-UHFFFAOYSA-N benzo[g][1,3]benzoselenazole Chemical compound C1=CC=CC2=C([se]C=N3)C3=CC=C21 IEICFDLIJMHYQB-UHFFFAOYSA-N 0.000 description 1
- IIUUNAJWKSTFPF-UHFFFAOYSA-N benzo[g][1,3]benzothiazole Chemical compound C1=CC=CC2=C(SC=N3)C3=CC=C21 IIUUNAJWKSTFPF-UHFFFAOYSA-N 0.000 description 1
- BVVBQOJNXLFIIG-UHFFFAOYSA-N benzo[g][1,3]benzoxazole Chemical compound C1=CC=CC2=C(OC=N3)C3=CC=C21 BVVBQOJNXLFIIG-UHFFFAOYSA-N 0.000 description 1
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- IAQRGUVFOMOMEM-UHFFFAOYSA-N but-2-ene Chemical group CC=CC IAQRGUVFOMOMEM-UHFFFAOYSA-N 0.000 description 1
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000003729 cation exchange resin Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001427 coherent effect Effects 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- MMJGQHYROJTOHX-JTQLQIEISA-N dibutyl (2s)-2-aminobutanedioate Chemical compound CCCCOC(=O)C[C@H](N)C(=O)OCCCC MMJGQHYROJTOHX-JTQLQIEISA-N 0.000 description 1
- 125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- ZZZGFHPVTUKOSU-FVGYRXGTSA-N ditert-butyl (2s)-2-aminopentanedioate;hydrate Chemical compound O.CC(C)(C)OC(=O)CC[C@H](N)C(=O)OC(C)(C)C ZZZGFHPVTUKOSU-FVGYRXGTSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- WBJINCZRORDGAQ-UHFFFAOYSA-N ethyl formate Chemical compound CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- ZFKJVJIDPQDDFY-UHFFFAOYSA-N fluorescamine Chemical compound C12=CC=CC=C2C(=O)OC1(C1=O)OC=C1C1=CC=CC=C1 ZFKJVJIDPQDDFY-UHFFFAOYSA-N 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229960003569 hematoporphyrin Drugs 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- MOFVSTNWEDAEEK-UHFFFAOYSA-M indocyanine green Chemical compound [Na+].[O-]S(=O)(=O)CCCCN1C2=CC=C3C=CC=CC3=C2C(C)(C)C1=CC=CC=CC=CC1=[N+](CCCCS([O-])(=O)=O)C2=CC=C(C=CC=C3)C3=C2C1(C)C MOFVSTNWEDAEEK-UHFFFAOYSA-M 0.000 description 1
- 229960004657 indocyanine green Drugs 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- SMBBZHGTZJNSRQ-UHFFFAOYSA-N n'-(6,6-dichlorohexyl)methanediimine Chemical compound ClC(Cl)CCCCCN=C=N SMBBZHGTZJNSRQ-UHFFFAOYSA-N 0.000 description 1
- VIJMMQUAJQEELS-UHFFFAOYSA-N n,n-bis(ethenyl)ethenamine Chemical compound C=CN(C=C)C=C VIJMMQUAJQEELS-UHFFFAOYSA-N 0.000 description 1
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003506 n-propoxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000005029 naphthylthio group Chemical group C1(=CC=CC2=CC=CC=C12)S* 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- XUZLXCQFXTZASF-UHFFFAOYSA-N nitro(phenyl)methanol Chemical compound [O-][N+](=O)C(O)C1=CC=CC=C1 XUZLXCQFXTZASF-UHFFFAOYSA-N 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000013307 optical fiber Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 125000000962 organic group Chemical group 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- MHYFEEDKONKGEB-UHFFFAOYSA-N oxathiane 2,2-dioxide Chemical compound O=S1(=O)CCCCO1 MHYFEEDKONKGEB-UHFFFAOYSA-N 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 125000004115 pentoxy group Chemical group [*]OC([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 description 1
- 125000003356 phenylsulfanyl group Chemical group [*]SC1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 208000007578 phototoxic dermatitis Diseases 0.000 description 1
- 231100000018 phototoxicity Toxicity 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 125000005920 sec-butoxy group Chemical group 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000001119 stannous chloride Substances 0.000 description 1
- 235000011150 stannous chloride Nutrition 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- USFPINLPPFWTJW-UHFFFAOYSA-N tetraphenylphosphonium Chemical compound C1=CC=CC=C1[P+](C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 USFPINLPPFWTJW-UHFFFAOYSA-N 0.000 description 1
- CBDKQYKMCICBOF-UHFFFAOYSA-N thiazoline Chemical compound C1CN=CS1 CBDKQYKMCICBOF-UHFFFAOYSA-N 0.000 description 1
- 125000002769 thiazolinyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- ARYHTUPFQTUBBG-UHFFFAOYSA-N thiophen-2-ylboronic acid Chemical compound OB(O)C1=CC=CS1 ARYHTUPFQTUBBG-UHFFFAOYSA-N 0.000 description 1
- NBOMNTLFRHMDEZ-UHFFFAOYSA-N thiosalicylic acid Chemical compound OC(=O)C1=CC=CC=C1S NBOMNTLFRHMDEZ-UHFFFAOYSA-N 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 238000002834 transmittance Methods 0.000 description 1
- IMFACGCPASFAPR-UHFFFAOYSA-N tributylamine Chemical class CCCCN(CCCC)CCCC IMFACGCPASFAPR-UHFFFAOYSA-N 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 238000012285 ultrasound imaging Methods 0.000 description 1
- 238000010977 unit operation Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 229910052724 xenon Inorganic materials 0.000 description 1
- FHNFHKCVQCLJFQ-UHFFFAOYSA-N xenon atom Chemical compound [Xe] FHNFHKCVQCLJFQ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0032—Methine dyes, e.g. cyanine dyes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0052—Small organic molecules
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Indole Compounds (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
- Investigating Materials By The Use Of Optical Means Adapted For Particular Applications (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Plural Heterocyclic Compounds (AREA)
- Endoscopes (AREA)
- Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
Abstract
【化1】
(式中、R1、R2、R7、及びR8は炭素数1〜10のアルキル基等を示し;R3、R4、R5、R6、R9、R10、R11、及びR12は水素原子、炭素数1〜6のアルキル基、アリール基等を示し;X1及びX2は炭素数1〜15のアルキル基またはアリール基を示し、X1及びX2は全部で0から4個のカルボキシル基を有し;m1、m2及びm3は0又は1を示し;L1〜L7は独立してメチン基を示し;Mは水素原子、金属、又は第4級アンモニウム塩を示し;nは電荷を中和するために必要な1〜7の整数を示す)
で表される化合物又はその医薬上許容される塩を含む、生体組織透過性に優れ腫瘍及び/又は血管の特異的な造影が可能な近赤外蛍光造影剤。
Description
で表される化合物又はその医薬上許容される塩を含む近赤外蛍光造影剤を提供する。
で表される基である。
で表される基である。
さらに好ましい態様によれば、Y1は−(CH2)pCONH−(ここでpは1から4の整数を示す)を表し、Y2は、−(CH2)−又は−(CH2)2−を表す。
で表される連結基を用いることができる。これらの炭化水素基は置換基を有していてもよく、1個以上のヘテロ原子を含んでいてもよい。例えばエーテル結合、チオエーテル結合、ジスルフィド結合、アミド結合、エステル結合、スルホアミド結合、又はスルホエステル結合を含んでいてもよい。
で表される結合基を用いることができる。Y1の好ましい例としては、下記式:
で表される基が挙げられる。
化合物1の合成経路を以下に示す。
出発物質1(20.9 g, 0.1 mol)、2−ブロモプロピオン酸(23.0 g, 0.15 mol)、及びo−ジクロロベンゼン(20 ml)を加熱し、140℃にて2時間攪拌した。反応終了後、その反応混合物にアセトン(200 ml)を加え、室温まで冷却し、その後生成した結晶を濾過して中間体1を得た(20.3 g、収率:56 %)
上記で得られた中間体1(10.0 g, 28 mmol)及び1,7−ジアザ−1,7−ジフェニル−1,3,5−ヘプタトリエン1塩酸塩(3.9 g, 14 mmol)をアセトニトリル(70 ml)及び水(11 ml)に溶解し、得られた溶液にトリエチルアミン(8.4 g, 91 mmol)及び無水酢酸(8.5 g, 91 mmol)を加え、その混合物を室温にて一晩攪拌した。反応混合物を0.1N塩酸(900 ml)に滴下し、沈殿した結晶を濾取した。この結晶をカラムクロマトグラフィー(展開溶媒:塩化メチレン:メタノール=95:5〜90:10)によって精製し、中間体2を得た(2.1 g、収率:12 %)。
上記で得られた中間体2(21.0 g, 1.5 mmol)、L−アスパラギン酸−ジ−t−ブチルエステル1水和物(1.3 g, 4.5 mmol)、4−ジメチルアミノピリジン(40 mg, 0.3 mmol)を塩化メチレン(50 ml)に溶解し、その溶液を氷上で冷却した。得られた溶液に1−エチル−3−(3−ジメチルアミノプロピル)−カルボジイミド塩酸塩(EDC)(700 mg, 4 mmol)及びトリエチレンアミン(340 mg、3 mmol)を加え、4℃にて一晩攪拌した。反応混合物に塩化メチレン(200 ml)及び1N塩酸(200 ml)を加え、その後塩化メチレン層を抽出し、飽和食塩水(200 ml)にて洗浄し、硫酸ナトリウムで乾燥させた。溶媒を減圧留去し、カラムクロマトグラフィー(展開溶媒:酢酸エチル:メタノール=95:5〜80:20)によって精製し、中間体3を得た(1.1 g、収率:64 %)。
中間体3 (500 mg, 0.5 mmol)をトルフルオロ酢酸 (5 ml)に溶解し、4℃にて一晩反応させ、その後トリフルオロ酢酸を減圧留去した。得られた残渣に水(50 ml) を加え、その後生じた結晶を濾取し、水及び酢酸エチルにて洗浄し、化合物1を得た(390 mg、収率: 90 %)。
化合物1を セファデックス (LH-20, ファルマシア製) (展開溶媒:メタノール)を用いたカラムクロマトグラフィーにて精製し、化合物2を得た。
化合物1を イオン交換樹脂カラムCR 11 (三菱化学製) に通すことにより、化合物3を得た。
1H-NMR (CD3OD)δ 1.98 (s, 12H), 2.70 (d, J=7.2Hz, 4H), 2.80 (t, J=7.2Hz, 4H), 3.30 (MeOH), 4.50 (t, J=7.2Hz, 4H), 4.60 (t, J=7.2Hz, 2H), 4.80 (H2O), 6.40 (d, J=13.2Hz, 2H), 6.63 (dd, J=13.2, 13.2Hz, 2H), 7.40-7.50 (m, 2H), 7.58-7.66 (m, 5H), 7.95-8.07 (m, 6H), 8.20 (d, J=7.2Hz, 2H)
1H-NMR (CD3OD)δ 1.99 (s, 12H), 2.72 (d, J=7.2Hz, 4H), 2.80 (t, J=7.2Hz, 4H), 3.30 (MeOH), 4.50 (t, J=7.2Hz, 4H), 4.60 (t, J=7.2Hz, 2H), 4.80 (H2O), 6.38 (d, J=13.2Hz, 2H), 6.61 (dd, J=13.2, 13.2Hz, 2H), 7.40-7.50 (m, 2H), 7.58-7.67 (m, 5H), 7.96-8.07 (m, 6H), 8.21 (d, J=7.2Hz, 2H)
1H-NMR (CD3OD)δ 1.98 (s, 12H), 2.56-2.65 (m, 4H), 2.75-2.85 (m, 4H), 3.30 (MeOH), 4.45-4.50 (m, 4H), 4.80 (H2O), 6.20 (d, J=13.2Hz, 2H), 6.65 (dd, J=13.2, 13.2Hz, 2H), 7.40-7.50 (m, 2H), 7.58-7.70 (m, 5H), 7.95-8.07 (m, 6H), 8.20 (d, J=7.2Hz, 2H)
化合物5を中間体1及び1,7−ジアザ−5−メチル−1,7−ジフェニル−1,3,5−ヘプタトリエン1水和物から化合物1と同様な手法によって合成した。
L−グルタミン酸−ジ−t−ブチルエステル1水和物をL−アスパラギン酸−ジ−t−ブチルエステル1水和物の代りに用いること以外は化合物1と同様な手法により、化合物6を中間体1及び1,7−ジアザ−5−メチル−1,7−ジフェニル−1,3,5−ヘプタトリエン1水和物から合成した。
1H-NMR (CD3OD)δ 1.80-2.15 (m, 4H), 2.01 (s, 12H), 2.28 (t, J=7.2Hz, 4H), 2.44 (s, 3H), 2.82 (t, J=7.2Hz, 4H), 3.31 (MeOH), 4.40-4.50 (m, 2H), 4.51 (t, J=7.2Hz, 4H), 4.88 (H2O), 6.42 (d, J=13.2Hz, 2H), 6.65 (d, J=13.2Hz, 2H), 7.42-7.50 (m, 2H), 7.57-7.67 (m, 4H), 7.95-8.05 (m, 4H), 8.10-8.27 (m, 4H)
化合物7を2,3,3−トリメチルインドレニンから化合物1と同様な手法により合成した。
1,7−ジアザ−5−メチル−1,7−ジフェニル−1,3,5−ヘプタトリエン1塩酸塩を1,7−ジアザ−1,7−ジフェニル−1,3,5−ヘプタトリエン1水和物の代りに用いること以外は化合物1と同様な手法により、化合物8を2,3,3−トリメチルインドレニンから合成した。
1H-NMR (CD3OD)δ 1.70 (s, 12H), 1.72-1.90 (m, 8H), 2.35-2.39 (m, 7H), 2.73-2.84 (m, 4H), 3.30 (MeOH), 4.08 (t, J=7.2Hz, 4H), 4.66 (t, J=7.2Hz, 2H), 4.89 (H2O), 6.33 (d, J=13.2Hz, 2H), 6.63 (d, J=13.2Hz, 2H), 7.18-7.50 (m, 8H), 8.05 (dd, J=13.2, 13.2 Hz, 2H)
化合物9を化合物1と同様の手法にて6-フェニル-2,3,3-トリメチルインドレニン(US特許番号 6,004,536の明細書に記載の方法によって合成)から合成した。
1H-NMR (CD3OD)δ 1.75 (s, 12H), 2.05-2.15 (m, 4H), 2.45-2.55 (m, 4H), 2.75-2.84 (m, 4H), 3.30 (MeOH), 4.20 (t, J=7.2Hz, 4H), 4.80 (H2O), 6.38 (J=13.2Hz, 2H), 6.62 (J=13.2Hz, 2H), 7.43-7.70 (m, 17H), 7.95 (dd, J=13.2, 13.2 Hz, 2H)
化合物10を化合物1と同様の手法にて6-ブロモ-2,3,3-トリメチルインドレニンから合成した。
1H-NMR (CD3OD)δ 1.68 (s, 12H), 2.00-2.15 (m, 4H), 2.40-2.55 (m, 4H), 2.77-2.92 (m, 4H), 3.30 (MeOH), 4.08 (t, J=7.2Hz, 4H), 4.82 (m, 2H), 6.38 (J=13.2Hz, 2H), 6.65 (J=13.2Hz, 2H), 7.30-7.40 (m, 4H), 7.50-7.72 (m, 3H), 7.90-8.02 (m, 2H)
化合物11を化合物1と同様の手法にて5-フェニル-2,3,3-トリメチル-インドレニンから合成した。
1H-NMR (CD3OD)δ 1.78 (s, 12H), 2.39 (s, 3H), 2.70-2.84 (m, 8H), 3.30 (MeOH), 4.30-4.46 (m, 4H), 4.60-4.68 (m, 2H), 6.39 (J=13.2Hz, 2H), 6.66 (J=13.2Hz, 2H), 7.30-7.48 (m, 9H), 7.56-7.72 (m, 3H), 8.05 (J=13.2Hz, 13.2Hz)
化合物13及び化合物14の合成経路を下記に示す。
1H-NMR (D2O)δ 1.73 (s, 12H), 2.50-2.65 (m, 4H), 2.68-2.73 (m, 4H), 4.28-4.38 (m, 4H), 4.39-4.50 (m, 2H), 4.90 (D2O), 6.47 (d, J=13.2Hz, 2H), 6.74 (t, J=13.2Hz, 2H), 7.40-7.50 (m, 2H), 7.60 (t, J=13.2Hz, 1H), 7.80-8.05 (m, 6H)
1H-NMR (D2O) δ 1.65 (s, 6H), 1.70 (s, 6H), 2.40 (d, J=7.2Hz, 2H), 2,58 (t, J=7.2Hz, 2H), 2.70 (t, J=7.2Hz, 2H), 4.18-4.30 (m, 4H), 4.90 (D2O), 6.18 (d, J=13,2Hz, 1H), 6.34 (d, J=13.2Hz, 1H), 6.48-6.62 (m, 2H), 7.20 (d, J=7.2Hz, 1H), 7.30 (d, J=7.2Hz, 1H), 7.48 (t, J=13.2Hz, 1H), 7.68-7.95 (m, 6H)
化合物15の合成経路を下記に示す。
1H-NMR (CD3OD)δ 2.00 (s, 12H), 2.72 (d, J=7.2Hz, 4H), 2.82 (t, J=7.2Hz, 4H), 3.30 (MeOH), 4.58 (t, J=7.2Hz, 4H), 4.70 (t, J=7.2Hz, 4H), 4.86 (H2O), 6.42 (d, J=13.2Hz, 2H), 6.62 (dd, J=13.2, 13.2Hz, 2H), 7.62-7.70 (m, 3H), 7.95-8.12 (m, 6H), 8.28 (d, J=7.2Hz, 2H), 8.42 (s, 2H)
化合物23の合成経路を下記に示す。
5-スルホ-2,3,3-トリメチルインドレイン(特開平2-233658号に記載の方法によって合成) (24.0 g, 0.1 mol)、2-ブロモプロピオン酸(23.0 g, 0.15 mol)、及びトリエチルアミン(10.1 g, 0.1 mol) を熱し、160℃ にて6時間攪拌した。反応終了後、反応混合物にメタノール(200 ml) を加え、室温まで冷却し、その後生じた結晶を濾取し、中間体6を得た(6.0 g、収率: 19.3 %)。
上記で得られた中間体1(3.1 g, 10 mmol) 及び1,7-ジアザ-1,7-ジフェニル -4-メチル-1,3,5-ヘプタトリエン1塩酸塩(特開平8-295658号 (1.5 g, 5 mmol) をメタノール(20 ml)に溶解し、得られた溶液にトリエチルアミン (2.5 g, 25 mmol)及び無水酢酸 (4.6 g, 45 mmol) を加え、その混合物を室温にて3時間攪拌した。反応混合物に酢酸ナトリウム(3.3 g, 33 mmol) を加え、室温にて30分間攪拌した。生じた結晶を濾取し、メタノール (20 ml)で洗浄して化合物23を得た(2.0 g、収率: 50.0 %).
1H-NMR (D2O)δ(ppm) 1.60 (s, 12H), 2.30 (s, 3H), 2.60 (t, 4H, J=7.2Hz), 4.20 (t, 4H, J=7.2Hz), 6.25 (d, 2H, J=14.5Hz), 6.55 (dd, 2H, 14.5, 14.5Hz), 7.25 (d, 2H, J=7.0Hz), 7.70-7.80 (m, 4H), 8.00 (dd, 2H, J=14.5, 14.5Hz)
化合物25及び化合物26の合成経路を下記に示す。
中間体6と同様の方法にて中間体7を5-スルホ-2,3,3-トリメチルインドレニン及びブロモ酢酸から合成した(16.6 g)。
化合物23と同様の手法にて、化合物25を中間体7及び中間体8(Zh. Org. Khim., 13, pp.1189-1192, 1977に記載の方法に従って得られた)から合成した(15.0 g)。
MS(FAB-, グリセリン) m/z = 844
化合物25 (4.2 g, 5 mmol) 及びトリエチルアミン (1.0g)を水 (20 ml)に加え、その後得られた溶液に o-メルカプト安息香酸(0.93 g, 6 mmol) を加え室温にて1時間攪拌した。得られた混合物に酢酸カリウム (2.0 g, 20 mmol)を加えた後、エタノール(20 ml)を加え、生じた結晶を濾取し、化合物26を得た(1.3 g、収率: 27%)
MS (FAB-, グリセリン) m/z = 962
化合物32の合成経路を下記に示す。
4-ブロモフェニルヒドラジン1塩酸塩 (73.8 g, 0.33 mmol) 及び 3-メチル-2-ブタノン (33.2 g, 0.40 mmmol) をエタノール (450 ml)に溶解し、得られた溶液に濃硫酸(7.5 ml) を添加し、8時間攪拌しながら還流した。混合物を室温まで冷却した後、溶液を減圧下100 mlまで濃縮した。その残渣に、水 (400 ml) 及び酢酸エチル(400 ml)を加えた後、水層のpHを 水酸化ナトリウム溶液にて7から8に調整した。得られた溶液を酢酸エチルにて抽出し、飽和食塩水にて洗浄し、無水硫酸ナトリウムで乾燥させた。得られた残渣をシリカゲルカラムクロマトグラフィー(展開溶媒:ヘキサン:酢酸エチル=5:1〜1:1) によって精製し、褐色液体として中間体9を得た(58.6 g、収率76 %)
中間体9(4.76 g, 20 mmol) 及びチオフェンボロン酸 (3.84 g, 30 mmol) をジメチルホルムアミド(50 ml)に加え、得られた溶液にパラジウムテトラキスフェニルホスフィン (1.16 g, 9 mmol) 及び塩化セシウム (13.3 g, 40 mmol) を加え、窒素雰囲気下100℃ にて 4 時間加熱し攪拌した。水(200 ml)を加えた後、混合物を酢酸エチル(200 ml)にて抽出し、飽和食塩水にて洗浄し、その後有機層を無水硫酸ナトリウムで乾燥し、溶媒を減圧留去した。残渣をシリカゲルカラムクロマトグラフィー(展開溶媒:ヘキサン:酢酸エチル=2:1 〜 1:1) によって精製し、褐色固体として中間体10を得た(2.8 g、収率: 58 %).
中間体10(1.40 g, 6 mmol) 及びトリエチルアミン(0.59 g, 6 mmol)をジメチルホルムアミド (3 ml)に加え、その混合物に2−クロルエタンスルホニルクロリド(1.42 g, 9 mmol) を氷冷下で滴下した。室温にて30分間攪拌を続けた後、その溶液に水酸化ナトリウム(0.23 g, 6 mmol) を水 (2 ml) に溶解することによって得られた溶液を加え、さらに室温にて1時間攪拌した。その混合物に、酢酸エチルを加え、上層をデカンテーションによって除去した。残渣を乾燥して中間体11を得た。その中間体11を更なる精製をすることなく次の反応に用いた。
上記で得られた中間体11及び1,7-ジアザ-1,7-ジフェニル-1,3,5-ヘプタトリエン1塩酸塩をメタノール(5 ml) に溶解し、得られた溶液にトリエチルアミン(160 mg, 2 mmol) 及び無水酢酸 (230 mg, 2 mmol)を加えた後、その混合物を室温にて7時間攪拌した。この混合物に酢酸エチル (20 ml) を加え沈殿した結晶を濾取し、酢酸エチル (10 ml)にて洗浄した。この結晶をメタノール (10 ml) に溶解した後、その溶液に飽和酢酸カリウムメタノール溶液(10 ml)を加えた。沈殿した結晶を濾取し、メタノール(5 ml)にて洗浄した。結晶をセファデックスLH-20 (希釈剤:メタノール)によって精製し、化合物32を得た (15 mg、収率: 2 % (中間体2から))。
1H-NMR (CD3OD)δ(ppm) 1.75 (s, 12H), 3.25 (t, 4H, J=7.2Hz), 4.50 (t, 4H, J=7.2Hz), 6.40 (d, 2H, J=14.5Hz), 6.63 (dd, 2H, 14.5, 14.5Hz), 7.07-7.12 (m, 2H), 7.33-7.45 (m, 6H), 7.53-7.75 (m, 5H), 7.96 (dd, 2H, J=14.5, 14.5Hz)
MS(FAB-, Glycerin) m/z = 760
化合物33の合成経路を下記に示す。
中間体10と同様の方法で中間体9及びジヒドロキシフェニルボランから中間体12を合成した(3.6 g、収率: 77 %).
中間体12 (1.40 g, 6 mmol) 及び1,4-ブタンサルトン (1.22 g, 9 mmol)をジメチルアセトアミド(2 ml) に溶解し、その溶液を135℃ にて5 時間攪拌した。その溶液に酢酸エチル(20 ml) を加え室温まで冷却し、その後沈殿した結晶を濾過し、酢酸エチルで洗浄して中間体13を得た (10 ml) (1.84 g、収率: 84 %)。
中間体13 (1110 mg, 3 mmol) 及び1,7-ジアザ-1,7-ジフェニル -1,3,5-ヘプタトリエン1塩酸塩 (285 mg, 1 mmol) をメタノール(5 ml)に溶解し、得られた溶液にトリエチルアミン(480 mg, 5 mmol) 及び無水酢酸 (670 mg, 7 mmol) を加え、その後室温にて7時間攪拌した。酢酸エチル (10 ml) を反応混合物に加え沈澱した結晶を濾取し、酢酸エチル(10 ml)にて洗浄した。結晶をメタノール (5 ml) に溶解し、飽和酢酸カリウムメタノール溶液(10 ml)を加え、結晶を濾過し、5 mlで洗浄した。結晶をセファデックス LH-20 (希釈剤 ;メタノール)にて精製し、化合物33を得た(250 mg、収率 : 30%)。
MS(FAB-, ニトロベンジルアルコール) m/z = 803
化合物33と同様の方法で化合物34を中間体9及び4-メチル-メルカプトフェニルボロン酸から合成した (15 mg)。
化合物35の合成経路を下記に示す。
3-アミノジフェニル(0.15 mol) 25.0 g をトリフルオロ酢酸100 mlに加え、その混合物を内部温度が0℃になるまで冷却した。その混合物に10.2 gの亜硝酸ナトリウム(0.15 mol)を水100 mlに溶解することによって得られた溶液を反応混合物の温度を5℃以下に保ちながら滴下した。滴下終了後、混合物を同温度で15分間攪拌し、その後、その混合物に塩化第一スズ100g(0.54 mol)を濃塩酸50 mlに溶解することによって得られた溶液を反応混合物の温度を10℃以下に保ちながら滴下した。滴下終了後、水250 mlの添加によって沈澱をした結晶を濾取し、塩化メチレン200 mlで洗浄した。得られた中間体14を乾燥し、精製せずに中間体15の合成に使用した。
上記で得られた中間体14(全量)及び3-メチル-2-ブタノン12.9 g (0.15 mol)を酢酸140 ml に加え、混合物を2時間30分攪拌しながら加熱した。混合物を室温まで冷却した後、沈澱した結晶を濾過によって除去し、濾液を4分の1量になるまで減圧濃縮した。残渣に水300 ml及び酢酸エチル300 ml を加え、不溶性の沈澱をセライトを用いて濾過によって除去した。ろ液を酢酸エチル (300 ml, 200 ml×2), にて抽出し、抽出物を飽和炭酸水素ナトリウム溶液及び飽和生理食塩水で洗浄し、その後硫酸ナトリウムで乾燥し、溶媒を減圧留去した。得られた残渣をシリカゲルクロマトグラフィー (展開溶媒: ヘキサン:酢酸エチル=3:1 〜 2:1)によって精製した。得られた結晶をヘキサン50 mlから再結晶し、13 gの中間体15を得た (収率: 4 %)
中間体13及び化合物33と同様の方法で化合物35を中間体15から合成した(65 mg)。
MS(FAB-, グリセリン) m/z = 842,804
1H-NMR (D2O) δ(ppm) 1.70 (s, 12H), 1.90-2.00 (m, 8H), 2.90 (t, 4H, J=7.2Hz), 4.10 (t, 4H, J=7.2Hz), 6.22 (d, 2H, J=14.5Hz), 6.55 (dd, 2H, 14.5, 14.5Hz), 7.30-7.60 (m, 17H), 7.77 (dd, 2H, J=14.5, 14.5Hz)
マウス大腸癌(コロン26カルシノーマ)由来の腫瘍組織片をBALB/cヌードマウス(5週齢、日本クレア株式会社)の左胸部皮下に移植した。10日後、直径約8 mmに腫瘍が成長したところでマウスを実験に使用した。蛍光励起光源には、チタンサファイアレーザーを使用した。レーザー光をリング型ライトガイド(株式会社住田光学ガラス)を用いて、被検マウスに均一に照射(照射の分散は10 %以内)した。照射光出力は、マウスの皮膚表面付近で約40μW/cm2になるように調整した。蛍光は、各化合物の極大励起波長で励起し、マウスからの蛍光発光を、短波長カットオフフィルター(IR84、IR86、IR88、富士写真フイルム株式会社)を介してCCDカメラ(C4880、浜松ホトニクス株式会社)で検出し、撮影した。カットオフフィルターは、使用した化合物の励起波長に合わせて選択した。また、露光時間は各化合物の蛍光強度に応じて調節した。試験化合物2を生理食塩水またはリン酸緩衝液(pH 7.4)に溶解し(0.5 mg/ml)、5.0 mg/kg用量でマウスの尾静脈から投与した。試験化合物投与の一定時間後にマウスをジエチルエーテルで麻酔し、マウス全身の蛍光画像を撮影した。比較として、ICG(5 mg/kg、静脈内)および下記の化合物(化合物A)を投与し、上記と同様の手法で造影を行った。結果を図1から図3に示す。
腫瘍を持っているマウスを試験例1と同様にして調製し、照射の条件は試験例1で説明した条件と同様にした。化合物5、化合物7、及び化合物10を試験化合物として用いた。各試験化合物(0.5 mg/ml)を生理食塩水又はリン酸緩衝液(pH 7.4)に溶解し、5.0 mg/kg用量で尾静脈からマウスに投与した。比較として、下記の化合物(化合物B、5 mg/kg、静脈内)をマウスに投与した。
Claims (11)
- 下記の式(I):
で表される化合物又はその医薬上許容される塩を含む近赤外蛍光造影剤。 - m1、m2及びm3のそれぞれが1である請求項1に記載の近赤外蛍光造影剤。
- X1が下記式(i):
で表される基である請求項1又は2に記載の近赤外蛍光造影剤。 - X1及びX2がそれぞれ独立して下記式(i):
で表される基である請求項1又は2に記載の近赤外蛍光造影剤。 - R3、R4、R5、R6、R9、R10、R11、及びR12の少なくとも1つは置換若しくは無置換のアリール基又は置換若しくは無置換のヘテロアリール基である請求項1から4のいずれか1項に記載の近赤外蛍光造影剤。
- R4、R5、R10、及びR11の少なくとも1つは置換若しくは無置換のアリール基又は置換若しくは無置換のヘテロアリール基であり;X1及びX2のそれぞれが独立して炭素数1〜5のカルボキシアルキル基又はスルホアルキル基である請求項1又は2に記載の近赤外蛍光造影剤。
- X1及びX2がそれぞれ独立して下記式:
で表される基である請求項1又は2に記載の近赤外蛍光造影剤。 - Y1が−(CH2)pCONH−(ここでpは1から4の整数を示す)を表し、Y2が、−(CH2)−又は−(CH2)2−を表す請求項3または4のいずれか1項に記載の近赤外蛍光造影剤。
- 腫瘍造影に用いられる請求項1〜8のいずれか1項に記載の近赤外蛍光造影剤。
- 血管造影に用いられる請求項1〜8のいずれか1項に記載の近赤外蛍光造影剤。
- 請求項1〜8のいずれか1項に記載の近赤外蛍光造影剤を生体内に導入する工程、該生体に励起光を照射する工程、及び該造影剤からの近赤外蛍光を検出する工程を含む蛍光造影法。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002109794A JP2003261464A (ja) | 2002-03-07 | 2002-03-07 | 近赤外蛍光造影剤および蛍光造影法 |
PCT/EP2003/002358 WO2003074091A2 (en) | 2002-03-07 | 2003-03-07 | Near infrared fluorescent contrast agent and method for fluorescence imaging |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2005519977A true JP2005519977A (ja) | 2005-07-07 |
Family
ID=27785574
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2002109794A Pending JP2003261464A (ja) | 2002-03-07 | 2002-03-07 | 近赤外蛍光造影剤および蛍光造影法 |
JP2003579524A Pending JP2005519977A (ja) | 2002-03-07 | 2003-03-07 | 近赤外蛍光造影剤および蛍光造影法 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2002109794A Pending JP2003261464A (ja) | 2002-03-07 | 2002-03-07 | 近赤外蛍光造影剤および蛍光造影法 |
Country Status (20)
Country | Link |
---|---|
US (2) | US7473415B2 (ja) |
EP (1) | EP1480683B1 (ja) |
JP (2) | JP2003261464A (ja) |
KR (1) | KR20040099301A (ja) |
CN (1) | CN100340298C (ja) |
AT (1) | ATE395088T1 (ja) |
AU (1) | AU2003208700B2 (ja) |
BR (1) | BR0308217A (ja) |
CA (1) | CA2478272A1 (ja) |
DE (1) | DE60320952D1 (ja) |
DK (1) | DK1480683T3 (ja) |
ES (1) | ES2305444T3 (ja) |
HK (1) | HK1079110A1 (ja) |
MX (1) | MXPA04008664A (ja) |
NO (1) | NO20044244L (ja) |
PL (1) | PL370918A1 (ja) |
PT (1) | PT1480683E (ja) |
RU (1) | RU2350355C9 (ja) |
WO (1) | WO2003074091A2 (ja) |
ZA (1) | ZA200408072B (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011046663A (ja) * | 2009-08-28 | 2011-03-10 | Fujifilm Corp | 近赤外蛍光造影剤 |
JP2011046662A (ja) * | 2009-08-28 | 2011-03-10 | Fujifilm Corp | 近赤外蛍光造影剤 |
JP2017141168A (ja) * | 2016-02-08 | 2017-08-17 | キヤノン株式会社 | 化合物又はその医薬上許容しうる塩、及び光学イメージング用造影剤 |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4445065A1 (de) * | 1994-12-07 | 1996-06-13 | Diagnostikforschung Inst | Verfahren zur In-vivo-Diagnostik mittels NIR-Strahlung |
JP2003261464A (ja) * | 2002-03-07 | 2003-09-16 | Fuji Photo Film Co Ltd | 近赤外蛍光造影剤および蛍光造影法 |
US7682602B2 (en) * | 2003-12-19 | 2010-03-23 | Konica Minolta Medical & Graphic, Inc. | Near-infrared fluorescent contrast medium |
US7233392B2 (en) * | 2004-03-25 | 2007-06-19 | Opotek, Inc. | Spectral imaging device with tunable light source |
US7910753B2 (en) * | 2004-09-10 | 2011-03-22 | Anaspec Incorporated | Cyanine dyes and their applications as luminescence quenching compounds |
US8227621B2 (en) | 2005-06-30 | 2012-07-24 | Li-Cor, Inc. | Cyanine dyes and methods of use |
WO2009012109A2 (en) * | 2007-07-13 | 2009-01-22 | Emory University | Cyanine-containing compounds for cancer imaging and treatment |
GB0718957D0 (en) * | 2007-09-28 | 2007-11-07 | Ge Healthcare Ltd | Optical imaging agents |
US20090214436A1 (en) * | 2008-02-18 | 2009-08-27 | Washington University | Dichromic fluorescent compounds |
US20090240143A1 (en) * | 2008-03-12 | 2009-09-24 | Mauna Kea Technologies | Method and an optical probe for in vivo imaging of a mucosa in a biliary or pancreatic system and a method for selectively operating a tissue sampling of a mucosa in a biliary or pancreatic system |
CN105288645A (zh) * | 2008-06-13 | 2016-02-03 | 西塞医疗中心 | 用于癌症靶向治疗的小分子配体-药物轭合物 |
EP2419478B1 (en) * | 2009-04-17 | 2018-02-28 | Li-Cor, Inc. | Fluorescent imaging with substituted cyanine dyes |
CN101574529B (zh) * | 2009-06-04 | 2011-04-20 | 中国人民解放军第三军医大学 | 近红外荧光化合物在制备用于淋巴结成像和血管造影的药物中的用途 |
AU2010286592B2 (en) | 2009-08-28 | 2015-08-13 | Visen Medical, Inc. | Systems and methods for tomographic imaging in diffuse media using a hybrid inversion technique |
US8401619B2 (en) | 2009-09-22 | 2013-03-19 | Visen Medical, Inc. | Systems and methods for virtual index-matching of diffusive media |
JP5462596B2 (ja) * | 2009-11-12 | 2014-04-02 | 富士フイルム株式会社 | 蛍光画像撮像装置 |
US8273875B2 (en) | 2009-11-16 | 2012-09-25 | University Of Notre Dame Du Lac | High performance luminescent compounds |
WO2012054784A1 (en) | 2010-10-20 | 2012-04-26 | Li-Cor, Inc. | Fluorescent imaging with substituted cyanine dyes |
JP5200192B2 (ja) | 2011-03-15 | 2013-05-15 | オリンパスメディカルシステムズ株式会社 | 医療装置 |
JP5200193B2 (ja) * | 2011-03-15 | 2013-05-15 | オリンパスメディカルシステムズ株式会社 | 医療装置 |
EP2806781B1 (en) | 2012-01-23 | 2018-03-21 | Washington University | Goggle imaging systems and methods |
CN104853669B (zh) | 2012-10-15 | 2017-07-21 | 文森医学公司 | 具有荧光及生物发光源的交叉形态加权特征的漫射介质成像的系统、方法及设备 |
EP3797798B1 (en) | 2013-03-14 | 2022-09-28 | Profusa, Inc. | Oxygen sensors |
WO2015103420A1 (en) | 2013-12-31 | 2015-07-09 | Memorial Sloan Kettering Cancer Center | Systems, methods, and apparatus for multichannel imaging of fluorescent sources in real time |
US10335501B2 (en) | 2014-12-15 | 2019-07-02 | Memorial Sloan Kettering Cancer Center | Cyclic peptides with enhanced nerve-binding selectively, nanoparticles bound with said cyclic peptides, and use of same for real-time in vivo nerve tissue imaging |
KR20160086481A (ko) * | 2015-01-09 | 2016-07-20 | 차의과학대학교 산학협력단 | 신규 유기 화합물 및 이를 포함하는 근적외선 형광 조영제, 그리고 조영제의 나노입자화 방법 |
US10806804B2 (en) | 2015-05-06 | 2020-10-20 | Washington University | Compounds having RD targeting motifs and methods of use thereof |
KR20180093961A (ko) | 2015-12-15 | 2018-08-22 | 메모리얼 슬로안-케터링 캔서 센터 | 조직 구별, 예를 들어, 수술 중 시각화를 위한 영상화 시스템 및 방법 |
CA3045007A1 (en) | 2016-11-30 | 2018-06-07 | Memorial Sloan Kettering Cancer Center | Inhibitor-functionalized ultrasmall nanoparticles and methods thereof |
CN115505280A (zh) * | 2016-12-21 | 2022-12-23 | 普罗菲尤萨股份有限公司 | 可聚合的近红外染料 |
CA3095410A1 (en) | 2018-03-30 | 2019-10-03 | Perkinelmer Health Sciences, Inc. | Systems and methods for 3d reconstruction of anatomical organs and inclusions using short-wave infrared (swir) projection tomography |
CN109824871B (zh) * | 2019-01-08 | 2021-04-16 | 南京邮电大学 | 一种近红外二区荧光醌式聚合物、制备方法及其应用 |
US11712482B2 (en) | 2019-12-13 | 2023-08-01 | Washington University | Near infrared fluorescent dyes, formulations and related methods |
EP4015004A1 (en) | 2020-12-18 | 2022-06-22 | Phi Pharma SA | Proteoglycan specific branched peptides |
WO2023210645A1 (ja) * | 2022-04-27 | 2023-11-02 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Icg脂質誘導体及びこれを含む脂質微粒子 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19539409C2 (de) * | 1995-10-11 | 1999-02-18 | Diagnostikforschung Inst | Kontrastmittel für die Nahinfrarot-Diagnostik |
DE19957007A1 (de) * | 1999-11-26 | 2001-05-31 | Few Chemicals Gmbh Wolfen | Cyaninfarbstoffe |
US6395257B1 (en) * | 2000-01-18 | 2002-05-28 | Mallinckrodt Inc. | Dendrimer precursor dyes for imaging |
JP2001288197A (ja) * | 2000-04-10 | 2001-10-16 | Fuji Photo Film Co Ltd | 蛍光ヌクレオチド |
WO2002012398A1 (fr) | 2000-08-08 | 2002-02-14 | Fuji Photo Film Co., Ltd. | Colorants à base de cyanine |
US6663847B1 (en) * | 2000-10-13 | 2003-12-16 | Mallinckrodt Inc. | Dynamic organ function monitoring agents |
JP2003261464A (ja) * | 2002-03-07 | 2003-09-16 | Fuji Photo Film Co Ltd | 近赤外蛍光造影剤および蛍光造影法 |
-
2002
- 2002-03-07 JP JP2002109794A patent/JP2003261464A/ja active Pending
-
2003
- 2003-03-07 DK DK03706606T patent/DK1480683T3/da active
- 2003-03-07 PL PL03370918A patent/PL370918A1/xx not_active Application Discontinuation
- 2003-03-07 AT AT03706606T patent/ATE395088T1/de not_active IP Right Cessation
- 2003-03-07 WO PCT/EP2003/002358 patent/WO2003074091A2/en active IP Right Grant
- 2003-03-07 BR BR0308217-2A patent/BR0308217A/pt not_active IP Right Cessation
- 2003-03-07 US US10/506,819 patent/US7473415B2/en not_active Expired - Fee Related
- 2003-03-07 KR KR10-2004-7013937A patent/KR20040099301A/ko not_active Application Discontinuation
- 2003-03-07 RU RU2004129766/15A patent/RU2350355C9/ru not_active IP Right Cessation
- 2003-03-07 PT PT03706606T patent/PT1480683E/pt unknown
- 2003-03-07 DE DE60320952T patent/DE60320952D1/de not_active Expired - Fee Related
- 2003-03-07 AU AU2003208700A patent/AU2003208700B2/en not_active Ceased
- 2003-03-07 MX MXPA04008664A patent/MXPA04008664A/es active IP Right Grant
- 2003-03-07 ES ES03706606T patent/ES2305444T3/es not_active Expired - Lifetime
- 2003-03-07 CA CA002478272A patent/CA2478272A1/en not_active Abandoned
- 2003-03-07 CN CNB038054604A patent/CN100340298C/zh not_active Expired - Fee Related
- 2003-03-07 EP EP03706606A patent/EP1480683B1/en not_active Expired - Lifetime
- 2003-03-07 JP JP2003579524A patent/JP2005519977A/ja active Pending
-
2004
- 2004-10-06 NO NO20044244A patent/NO20044244L/no not_active Application Discontinuation
- 2004-10-06 ZA ZA200408072A patent/ZA200408072B/en unknown
-
2005
- 2005-12-08 HK HK05111271A patent/HK1079110A1/xx not_active IP Right Cessation
-
2008
- 2008-06-27 US US12/147,717 patent/US20090041670A1/en not_active Abandoned
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011046663A (ja) * | 2009-08-28 | 2011-03-10 | Fujifilm Corp | 近赤外蛍光造影剤 |
JP2011046662A (ja) * | 2009-08-28 | 2011-03-10 | Fujifilm Corp | 近赤外蛍光造影剤 |
US8765961B2 (en) | 2009-08-28 | 2014-07-01 | Fujifilm Corporation | Near infrared fluorescent imaging agent |
JP2017141168A (ja) * | 2016-02-08 | 2017-08-17 | キヤノン株式会社 | 化合物又はその医薬上許容しうる塩、及び光学イメージング用造影剤 |
Also Published As
Publication number | Publication date |
---|---|
WO2003074091A3 (en) | 2004-03-11 |
PL370918A1 (en) | 2005-06-13 |
EP1480683A2 (en) | 2004-12-01 |
ES2305444T3 (es) | 2008-11-01 |
DK1480683T3 (da) | 2008-08-18 |
RU2350355C9 (ru) | 2009-05-27 |
PT1480683E (pt) | 2008-07-24 |
HK1079110A1 (en) | 2006-03-31 |
US20090041670A1 (en) | 2009-02-12 |
ZA200408072B (en) | 2006-06-28 |
RU2350355C2 (ru) | 2009-03-27 |
RU2004129766A (ru) | 2005-08-10 |
CN1638810A (zh) | 2005-07-13 |
ATE395088T1 (de) | 2008-05-15 |
CA2478272A1 (en) | 2003-09-12 |
CN100340298C (zh) | 2007-10-03 |
WO2003074091A2 (en) | 2003-09-12 |
US20050226815A1 (en) | 2005-10-13 |
KR20040099301A (ko) | 2004-11-26 |
BR0308217A (pt) | 2004-12-21 |
US7473415B2 (en) | 2009-01-06 |
MXPA04008664A (es) | 2004-12-06 |
JP2003261464A (ja) | 2003-09-16 |
AU2003208700A1 (en) | 2003-09-16 |
EP1480683B1 (en) | 2008-05-14 |
AU2003208700B2 (en) | 2007-12-20 |
NO20044244L (no) | 2004-12-06 |
DE60320952D1 (de) | 2008-06-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1480683B1 (en) | Near infrared fluorescent contrast agent and method for fluorescence imaging | |
KR100531708B1 (ko) | 근적외 형광 조영제 및 형광 영상화 | |
AU2010210547B2 (en) | Charge-balanced imaging agents | |
CA2394539C (en) | Near infrared fluorescent contrast agent and fluorescence imaging | |
JP6560766B2 (ja) | 目の血管系を評価するための組成物及び方法 | |
JP2010195764A (ja) | 新規化合物、該新規化合物を用いたプローブ及び該新規化合物もしくは該プローブを用いた蛍光イメージング用造影剤 | |
CA2413033A1 (en) | Near infrared fluorescent contrast agent and fluorescence imaging | |
JP3507060B2 (ja) | 近赤外蛍光造影剤及び蛍光イメージング | |
JP2003510294A (ja) | 手術中に腫瘍の周縁を視覚化するための、血管新生の標的構造物に対する抗体−色素結合物 | |
JP2023525601A (ja) | 腫瘍組織を標識するための新規蛍光化合物 | |
JP2005120026A (ja) | 近赤外蛍光造影剤 | |
JP2009067690A (ja) | メロシアニン色素を含む蛍光造影剤 | |
JP2005145819A (ja) | 蛍光造影剤および体外蛍光造影方法 | |
JP2005170812A (ja) | 蛍光造影剤及び蛍光造影方法 | |
JP2005145921A (ja) | 診断用蛍光造影剤及び蛍光造影診断方法 | |
CZ20022092A3 (cs) | Fluorescenční kontrastní činidlo vyzařující záření v blízké infračervené oblasti a použití tohoto činidla při fluorescenčním zobrazování | |
CZ2001987A3 (cs) | Fluorescenční kontrastní činidlo vyzařující záření v blízké infračervené oblasti a použití tohoto činidla při fluorescenčním zobrazování |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060119 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A712 Effective date: 20061214 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090303 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090601 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20090728 |